公司治理方面，泰恩康构建了完善的现代企业治理结构，管理层坚守长期主义，股份解禁后无减持计 划，以实际行动彰显发展信心。同时，公司搭建全球化医药创新共享平台，通过内生增长与外延合作并 举，聚合外部研发力量，加速first-in-class创新药研发，CKBA软膏等项目进展顺利，展现了创新活力。 未来，泰恩康将以此次获奖为契机，持续深化ESG融入企业发展战略，在坚守医药企业社会责任、保障 产品质量安全的同时，加大创新药布局力度，完善研发梯队建设，以更优质的医药健康产品服务社会， 在可持续发展道路上稳步前行，为社会创造更大价值。 中证报中证网讯（ 王珞）11月26日，由中国证券报、中国国新主办，国新证券承办的2025金牛企业可 持续发展论坛暨第三届国新杯·ESG金牛奖颁奖典礼在苏州举行。泰恩康（301263）凭借在ESG领域的 卓越实践与快速成长，成功斩获"ESG新锐金牛奖二十强"殊荣。 作为聚焦医药健康领域的创新型企业，泰恩康的ESG实践始终紧扣行业特性，以"创新+责任"双轮驱动 发展。在环境维度，公司优化生产流程，推行绿色制造理念，从原材料采购到废弃物处理全链条把控环 保标准，助力医药行业低碳转型。社会价值层面 ...

Core Viewpoint - The stock of Taiankang has shown significant volatility, with a year-to-date increase of 100.53%, but recent trends indicate a decline over the past 20 and 60 days, raising concerns about its future performance [1][2]. Financial Performance - For the period from January to September 2025, Taiankang reported a revenue of 526 million yuan, representing a year-on-year decrease of 8.13% [2]. - The net profit attributable to the parent company for the same period was 31.41 million yuan, reflecting a substantial year-on-year decline of 73% [2]. Stock Market Activity - As of November 26, Taiankang's stock price was 29.66 yuan per share, with a market capitalization of 12.62 billion yuan [1]. - The trading volume on that day was 66.90 million yuan, with a turnover rate of 0.75% [1]. - The stock has experienced a net outflow of 4.76 million yuan in principal funds, indicating a lack of strong buying interest [1]. Shareholder Information - As of September 30, the number of shareholders for Taiankang increased to 12,000, a rise of 9.32% from the previous period [2]. - The average number of circulating shares per shareholder decreased by 8.53% to 25,381 shares [2]. Dividend Distribution - Since its A-share listing, Taiankang has distributed a total of 460 million yuan in dividends, with 377 million yuan distributed over the past three years [3].

Core Viewpoint - The company, Tai En Kang, is poised to address a significant unmet clinical need in the treatment of pediatric vitiligo, with its innovative drug CKBA potentially becoming the first approved treatment for children aged 2-12 years [1] Group 1: Market Opportunity - There are currently no approved drugs for vitiligo in children aged 2-12 globally, and existing therapies are often used off-label [1] - The estimated number of vitiligo patients in China exceeds 30 million, with children accounting for approximately 32%-40% of this population, indicating a substantial market demand [1] - The annual treatment cost for pediatric vitiligo is estimated to be between 15,000 to 20,000 yuan, suggesting a market size exceeding 100 billion yuan [1] Group 2: Product Development - CKBA, derived from natural products like frankincense, is a new immunomodulator that offers greater targeting and safety compared to traditional immunosuppressants, making it particularly suitable for pediatric use [1] - The company anticipates that CKBA cream could be approved as the first innovative drug for treating vitiligo in children aged 2-12, and it is expected to become the preferred option for maintenance therapy [1] - Projections indicate that, once approved, the annual peak sales for CKBA in the pediatric vitiligo market could exceed 5 billion yuan [1] Group 3: Regulatory Progress - On November 20, the company announced that its subsidiary, Bo Chuang Yuan, has had the application for CKBA cream (Class 1 chemical drug) for pediatric vitiligo Phase II clinical trials accepted by the National Medical Products Administration [1]

Group 1 - The core viewpoint of the article highlights that TianKang (SZ 301263) will hold an investor meeting on November 21, 2025, where the company's Vice President and Secretary of the Board, Li Ting, will address investor inquiries [1] - For the year 2024, TianKang's revenue composition is as follows: 61.1% from pharmaceutical agency, 37.28% from pharmaceutical manufacturing, 1.51% from pharmaceutical technology services, and 0.12% from other businesses [1] - As of the report, TianKang's market capitalization stands at 12.1 billion yuan [1]

Core Viewpoint - The company, 泰恩康, announced the release of a portion of shares pledged by its controlling shareholder, indicating a potential positive shift in shareholder confidence and liquidity [1]. Group 1: Shareholder Actions - The controlling shareholder, 孙伟文, has released 6.72 million shares from pledge [1]. - As of the announcement date, the total number of pledged shares by 郑汉杰 is 35.5 million, representing 40.17% of his holdings [1]. - 孙伟文 has pledged a total of 7.9 million shares, which accounts for 11.93% of her holdings [1]. Group 2: Financial Performance - For the year 2024, the revenue composition of 泰恩康 is as follows: 61.1% from pharmaceutical agency, 37.28% from pharmaceutical manufacturing, 1.51% from pharmaceutical technology services, and 0.12% from other businesses [1]. - The current market capitalization of 泰恩康 is 12.1 billion yuan [1].

Group 1: Clinical Trial Overview - The company has received approval from the National Medical Products Administration for a Phase II clinical trial of CKBA cream for treating vitiligo in children aged 2-12 years, with a total of 30 patients enrolled over a 24-week period [3][4]. - The study showed that the 1.5% CKBA cream combined with NB-UVB therapy resulted in a VASI score improvement of -56.53%, significantly better than the control group’s -16.67% (P=0.0029) [3][4]. - The exploratory study validated the effectiveness and safety of the CKBA cream in pediatric vitiligo patients, providing a basis for larger-scale trials [3][4]. Group 2: Market Potential and Demand - There are currently no approved drugs for pediatric vitiligo globally, with an estimated 30 million vitiligo patients in China, of which 32%-40% are children [4][5]. - The annual treatment cost for pediatric vitiligo is estimated at 15,000 to 20,000 CNY, suggesting a market potential exceeding 100 billion CNY [4][5]. - If approved, CKBA is projected to achieve annual sales exceeding 5 billion CNY in the pediatric vitiligo market [4][5]. Group 3: Competitive Landscape - CKBA is the first innovative drug in China to conduct Phase II clinical trials for children under 12 with vitiligo, with no existing approved treatments [5][6]. - The drug's unique mechanism as an immune modulator offers targeted treatment, making it safer and more suitable for children compared to traditional immunosuppressants [4][5]. Group 4: Future Development Plans - The company plans to submit an application for a Phase III clinical trial for adult vitiligo based on the successful completion of Phase II trials [5][6]. - There are ongoing preparations for a Phase II/III clinical trial for CKBA in treating rosacea, with an IND application for Alzheimer's disease planned for the second half of 2026 [6][9]. - The company anticipates significant revenue growth in 2026 and explosive growth in 2027 as new products are approved [10].

证券代码：301263 证券简称：泰恩康 公告编号：2025-077 广东泰恩康医药股份有限公司 关于控股股东、实际控制人部分股份解除质押的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 广东泰恩康医药股份有限公司（以下简称"公司"）于近日收到公司控股股东、 实际控制人孙伟文女士的通知，获悉其所持有的公司部分股份办理了解除质押的 手续，具体情况如下： | 股东 | 是否为控股股 东或第一大股 | 本次解除 | 占其所 持股份 | 占公司总 | 质押 | 质押 | | | --- | --- | --- | --- | --- | --- | --- | --- | | 名称 | 东及其一致行 | 质押数量 （股） | 比例 | 股本比例 | 起始日 | 解除日 | 质权人 | | | 动人 | | （%） | （%） | | | | | 孙伟文 | 是 | 6,720,000 | 10.15 | 1.58 | 2024-12-09 | 2025-11-20 | 渤海国际 信托股份 | | | | | | | | | 有限公司 | | 合计 | - | 6 ...

Core Insights - Guangdong Tianenkang Pharmaceutical Co., Ltd. has received a notice of acceptance from the National Medical Products Administration for its clinical trial application of CKBA ointment combined with narrowband ultraviolet B (NB-UVB) for treating non-segmental vitiligo in children aged 2 to 12 [1][2] - This marks a significant step for Tianenkang in the innovative treatment of pediatric vitiligo, potentially offering new hope for affected children and their families [1] - The CKBA ointment, a first-in-class immunomodulator targeting ACC1/MFE-2, demonstrates a unique mechanism of action by inhibiting the differentiation of CD8+ T cells and downregulating the expression of IFN-γ and IL-17, thereby improving the immune environment of the skin [1][2] Company Development - CKBA is recognized as the world's first drug targeting T cell fatty acid metabolism pathways, developed from natural products by a team from Shanghai Jiao Tong University, highlighting its innovative value and clinical potential [2] - The acceptance of the clinical trial application represents another important milestone in Tianenkang's journey of innovative drug development, reflecting the company's commitment to addressing unmet clinical needs and building a high-quality pipeline of innovative drugs [2] - Tianenkang aims to continue its focus on the pharmaceutical health sector, striving for more innovative outcomes to safeguard public health and create long-term value for investors [2]

Core Insights - Guangdong Taiankang Pharmaceutical Co., Ltd. has made significant progress in the innovative treatment of pediatric vitiligo with the acceptance of its clinical trial application for CKBA cream combined with narrowband ultraviolet B (NB-UVB) for children aged 2-12 [1][2] - The global prevalence of vitiligo, a chronic autoimmune disease characterized by skin pigment loss, is high, with children accounting for 32%-40% of cases, highlighting a substantial unmet clinical need in this demographic [1] Group 1 - The acceptance of the clinical trial application marks a key advancement for the company in the pediatric vitiligo treatment sector, potentially providing new options for affected children and their families [1] - Currently, there are no approved products for treating vitiligo in children globally, indicating a significant market opportunity for the company [1] - The company aims to address unmet clinical needs and enhance its innovative drug pipeline, reinforcing its commitment to public health and long-term value creation for investors [2] Group 2 - CKBA, a First-in-Class innovative drug with global intellectual property rights, is progressing steadily in its indication layout, with adult vitiligo in Phase II trials and plans for Phase III submission [2] - The company is also preparing for II/III phase trials for rosacea and advancing preclinical research for Alzheimer's disease, with an IND application planned for the second half of 2026 [2] - The acceptance of the pediatric vitiligo indication further enriches the company's indication matrix, showcasing its deep accumulation in innovative drug research and development [2]

Core Viewpoint - The announcement by TianKang regarding the approval of a Phase II clinical trial for CKBA cream in treating non-segmental vitiligo in children aged 2-12 is a significant development, potentially positioning CKBA as the first targeted therapy for this condition in children, addressing a gap in treatment options [2]. Group 1 - TianKang's subsidiary, Jiangsu BoChuangYuan Biopharmaceutical Technology Co., Ltd., received a notice from the National Medical Products Administration approving the application for a Phase II clinical study [2]. - The clinical trial will assess the safety, efficacy, and pharmacokinetic characteristics of CKBA cream combined with narrowband ultraviolet B in children with non-segmental vitiligo [2]. - Following the approval, the company plans to expedite the Phase II clinical trial for pediatric vitiligo, indicating a strong commitment to advancing this innovative treatment [2].